Protocol Ledger

Clinical Cooperative Network · Consolidated Sponsor Hub

ETOP IBCSG Partners Foundation: Clinical Trials & FDA Approval Profile

ETOP IBCSG Partners Foundation (Global / Institutional) sponsors 17 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (5 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)23.5%
Median Closed Enrollment vs National (145 pts)147 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for ETOP IBCSG Partners Foundation
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)17
Active Pipeline (Recruiting Now)9 (5)
Completed vs Stopped Early4 / 4 (23.5%)
Median Closed Actual Enrollment147 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With ETOP IBCSG Partners Foundation
Hospital Research SiteLocationShared Protocols
Kantonsspital St. GallenSankt Gallen6
Inselspital BernBern5
CHU AngersAngers5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by ETOP IBCSG Partners Foundation
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05718323Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCPhase IIRECRUITING
NCT05522660Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small CePhase IIIRECRUITING
NCT06284317A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-Phase IIIRECRUITING
NCT06931717A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung CaPhase IIIRECRUITING
NCT04908956Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)Phase IITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the ETOP IBCSG Partners Foundation Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI